Covax-19™

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Covax-19™
Accession Number
DB15846
Description

Covax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. This adjuvant is designed to circumvent high fevers, fatigue, and aches experienced with other vaccines using more traditional adjuvants. Covax-19™ was tested in animal studies, and shown to achieve potent antibody and T-cell responses against the COVID-19 spike protein. As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073). Phase 2 and 3 trials are planned for September 2020, and the vaccine is expected to launch early in 2021.

Type
Biotech
Groups
Investigational
Synonyms
Not Available
External IDs
  • Covax-19™

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Not Available
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Tomar J, Patil HP, Bracho G, Tonnis WF, Frijlink HW, Petrovsky N, Vanbever R, Huckriede A, Hinrichs WLJ: Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge. J Control Release. 2018 Oct 28;288:199-211. doi: 10.1016/j.jconrel.2018.09.006. Epub 2018 Sep 12. [PubMed:30218687]
  2. Wanandy T, Honda-Okubo Y, Davies NW, Rose HE, Heddle RJ, Brown SGA, Woodman RJ, Petrovsky N, Wiese MD: Pharmaceutical and preclinical evaluation of Advax adjuvant as a dose-sparing strategy for ant venom immunotherapy. J Pharm Biomed Anal. 2019 Aug 5;172:1-8. doi: 10.1016/j.jpba.2019.04.017. Epub 2019 Apr 9. [PubMed:31009889]
  3. Rego GNA, Nucci MP, Alves AH, Oliveira FA, Marti LC, Nucci LP, Mamani JB, Gamarra LF: Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2. Vaccines (Basel). 2020 Aug 25;8(3). pii: vaccines8030474. doi: 10.3390/vaccines8030474. [PubMed:32854391]
  4. Information on Covax-19 [Link]
  5. Vaxine announcement [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Not Yet RecruitingTreatmentCOVID / COVID - 19 / Novel Coronavirus Infectious Disease (COVID-19)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on September 17, 2020 13:11 / Updated on September 18, 2020 02:47

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates